{"protocolSection": {"identificationModule": {"nctId": "NCT02045875", "orgStudyIdInfo": {"id": "RC-5816"}, "organization": {"fullName": "Asthma Management Systems", "class": "INDUSTRY"}, "briefTitle": "Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence", "officialTitle": "Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence"}, "statusModule": {"statusVerifiedDate": "2018-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-03-04", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-07-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-07-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-01-23", "studyFirstSubmitQcDate": "2014-01-23", "studyFirstPostDateStruct": {"date": "2014-01-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-05-11", "resultsFirstSubmitQcDate": "2018-06-19", "resultsFirstPostDateStruct": {"date": "2018-06-20", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-06-19", "lastUpdatePostDateStruct": {"date": "2018-06-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Asthma Management Systems", "class": "INDUSTRY"}, "collaborators": [{"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, {"name": "West Penn Allegheny Health System", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "40 subjects with moderate-to-severe asthma will be randomly selected for study in which 20, will be monitored for medication use (Dulera 100/5, Dulera 200/5 and Proventil HFA) over 3 months. These intervention subjects will receive medication use feedback at each visit, while the control group will receive the standard of asthma care. Those interventional subjects with Dulera adherence\\<60% will receive feedback based on an asthma adherence disease management model protocol, Asthma Adherence Pathway. Intervention clinicians will been trained in Motivational Interviewing to reduce subject ambivalence about medication use. The primary hypothesis is that subjects who receive medication monitoring and Motivational Interviewing adherence strategies will have better asthma control, as measured by the Asthma Control Questionnaire, than the control group.", "detailedDescription": "Primary Clinical Hypothesis: Poorly controlled subjects with moderate-to-severe asthma (measured by Asthma Control Questionnaire (ACQ) \u2265 1) despite treatment with Dulera, who are treated with the asthma adherence disease management protocol, Asthma Adherence Pathway\u2122, will achieve greater asthma control than similar control subjects who are treated with the current standard of care.\n\nPrimary end point: There will be four measures of Asthma Control Questionnaire (ACQ) over time over 3 months. The primary endpoint is the third month measure of ACQ.\n\nSecondary Clinical Hypothesis: The asthma adherence disease management program, Asthma Adherence Pathway\u2122, will increase observed adherence to Dulera relative to a benchmark of 60% adherence (i.e., expected prescribed actuations).\n\nSecondary end points: a) Average adherence to Dulera over the three month study period\n\nTertiary Clinical Hypothesis: Responses to Adult Asthma Adherence Questionnaire (AAAQ) will be related to Dulera Adherence\n\nTertiary Study Endpoints: There will be 2 measures of the AAAQ (first and last visit) and the tertiary endpoint is the last visit"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Adherence monitoring", "Motivational Interviewing Adherence strategies"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 50, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dulera adherence monitoring", "type": "EXPERIMENTAL", "description": "Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence", "interventionNames": ["Drug: Dulera"]}, {"label": "Dulera Standard of Asthma Care", "type": "ACTIVE_COMPARATOR", "description": "Dulera standard of asthma care", "interventionNames": ["Drug: Dulera"]}], "interventions": [{"type": "DRUG", "name": "Dulera", "description": "Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.", "armGroupLabels": ["Dulera Standard of Asthma Care", "Dulera adherence monitoring"], "otherNames": ["mometasone furoate/formoterol fumarate dihydrate"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Asthma Control", "description": "Asthma Control Questionnaire measured at each office visit. ACQ integrates values by 6 clinical questions related to symptoms and the value related to FEV1% predicted with a total score ranging from 0-6 and higher values indicating poorer asthma control.", "timeFrame": "Baseline, one, two and three months"}], "secondaryOutcomes": [{"measure": "Adherence to Dulera 100/5 and 200/5", "description": "Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark\n\nAdherence was calculated by taking the number of doses actually taken divided by the number of doses prescribed and multiplying by 100.", "timeFrame": "week 2. months 1, 2, and 3"}, {"measure": "Overall Adherence to Dulera 100/5 and 200/5", "description": "Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark\n\nOverall interval value was the mean of daily percent", "timeFrame": "3 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Physician diagnosis of asthma of moderate severity\n2. Subjects \u2265 18 years of age\n3. Currently receiving an inhaled corticosteroid medication and being prescribed Dulera 100/5 as part of standard of care based upon asthma severity and dosing guidelines\n4. Asthma Control Questionnaire (ACQ) result \\> 1.0 at entry\n5. Demonstration of correct inhalation technique for use of meter-dosed inhalers (MDIs)\n6. History of reversible airway obstruction documented by treating physician Exclusion Criteria: intermittent asthma; emphysema, chronic obstructive pulmonary disease; chronic bronchitis; cystic fibrosis; medication that may have a drug interaction with Dulera\n\nExclusion Criteria\n\n1. Intermittent asthma (asthma exacerbations or symptoms \\< 3 days/week)\n2. Diagnosis of emphysema in prior year\n3. Diagnosis at any time of: chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, bronchiectasis, Churg Strauss, Wegener's, sarcoidosis, pulmonary hypertension or lung cancer\n4. On any medication documented to have a drug interaction with Dulera", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Deborah Gentile, DO", "affiliation": "West Penn Allegheny Health System", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "West Penn Allegheny Health System", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15212", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Dulera Adherence Monitoring", "description": "Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence\n\nDulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older."}, {"id": "FG001", "title": "Dulera Standard of Asthma Care", "description": "Dulera standard of asthma care\n\nDulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "27"}, {"groupId": "FG001", "numSubjects": "23"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Dulera Adherence Monitoring", "description": "Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence\n\nDulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older."}, {"id": "BG001", "title": "Dulera Standard of Asthma Care", "description": "Dulera standard of asthma care\n\nDulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "41", "lowerLimit": "23", "upperLimit": "67"}, {"groupId": "BG001", "value": "39", "lowerLimit": "26", "upperLimit": "69"}, {"groupId": "BG002", "value": "40", "lowerLimit": "23", "upperLimit": "69"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "27"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "13"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Asthma Control", "description": "Asthma Control Questionnaire measured at each office visit. ACQ integrates values by 6 clinical questions related to symptoms and the value related to FEV1% predicted with a total score ranging from 0-6 and higher values indicating poorer asthma control.", "populationDescription": "All patients who completed ACQ at 4 clinical visits were included in the analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, one, two and three months", "groups": [{"id": "OG000", "title": "Dulera Adherence Monitoring", "description": "Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence\n\nDulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older."}, {"id": "OG001", "title": "Dulera Standard of Asthma Care", "description": "Dulera standard of asthma care\n\nDulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"title": "baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.857", "spread": "0.924"}, {"groupId": "OG001", "value": "1.592", "spread": "0.839"}]}]}, {"title": "one month", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.792", "spread": "1.359"}, {"groupId": "OG001", "value": "1.578", "spread": "0.855"}]}]}, {"title": "two month", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.345", "spread": "1.184"}, {"groupId": "OG001", "value": "1.488", "spread": "0.947"}]}]}, {"title": "three month", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.105", "spread": "0.806"}, {"groupId": "OG001", "value": "1.407", "spread": "0.759"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.046", "pValueComment": "Effect of interaction of time and treatment group", "statisticalMethod": "ANOVA"}]}, {"type": "SECONDARY", "title": "Adherence to Dulera 100/5 and 200/5", "description": "Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark\n\nAdherence was calculated by taking the number of doses actually taken divided by the number of doses prescribed and multiplying by 100.", "populationDescription": "Data was only collected in the interventional group.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent of prescribed doses", "timeFrame": "week 2. months 1, 2, and 3", "groups": [{"id": "OG000", "title": "Dulera Adherence Monitoring", "description": "Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence\n\nDulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}]}], "classes": [{"title": "week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "88.75", "spread": "10.43"}]}]}, {"title": "month 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "80.7", "spread": "14.52"}]}]}, {"title": "month 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "77.55", "spread": "19.13"}]}]}, {"title": "month 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.8", "spread": "19.83"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "paramType": "correlation coefficient", "paramValue": "-0.508", "ciNumSides": "TWO_SIDED", "estimateComment": "correlation of asthma control and adherence"}]}, {"type": "SECONDARY", "title": "Overall Adherence to Dulera 100/5 and 200/5", "description": "Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark\n\nOverall interval value was the mean of daily percent", "populationDescription": "Data was only collected in the interventional group.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent of prescribed doses per day", "timeFrame": "3 months", "groups": [{"id": "OG000", "title": "Dulera Adherence Monitoring", "description": "Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence\n\nDulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "80.95", "spread": "14.23"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "3 months", "eventGroups": [{"id": "EG000", "title": "Dulera Adherence Monitoring", "description": "Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence\n\nDulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.", "deathsNumAffected": 0, "deathsNumAtRisk": 27, "seriousNumAffected": 0, "seriousNumAtRisk": 27, "otherNumAffected": 0, "otherNumAtRisk": 27}, {"id": "EG001", "title": "Dulera Standard of Asthma Care", "description": "Dulera standard of asthma care\n\nDulera: Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 0, "otherNumAtRisk": 23}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Andrew G Weinstein MD", "organization": "Asthma Management Systems", "email": "agwmd@aol.com", "phone": "302 893 5455"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2014-01-06", "uploadDate": "2018-05-08T07:52", "filename": "Prot_SAP_000.pdf", "size": 855092}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068656", "term": "Mometasone Furoate"}, {"id": "D000068759", "term": "Formoterol Fumarate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "Tea", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Channel", "relevance": "HIGH"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}